Back to discover
Drug

Hydrogen

In clinical development
Emerging researchLate-stage development

Also known as Dihydrogen, Molecular hydrogen, Protium.

3
Research papers
3
Active clinical trials
Latest activity
beta

Recent clinical, regulatory, research and industry developments relating to this drug.

Hydrogen supply chains across Chinese provinces for production and transportation

Industry2026-08-03Manufacturing · Nature — Climate Sciences

Hydrogen's Feasibility and Safety as a Therapy in Extracorporeal Cardiopulmonary Resuscitation

Clinical trial2025-07-03Results expected Q1 2027 · ClinicalTrials.gov

Single-Atom Catalysts: A Sustainable Pathway for the Advanced Catalytic Applications.

Research2021-02-24Small (Weinheim an der Bergstrasse, Germany)

Profile

Identifiers & mechanism

Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.

Canonical name
Hydrogen
Aliases & brands
DihydrogenMolecular hydrogenProtium
RxNorm CUI
5497
ChEMBL ID
CHEMBL4297766
UNII
7YNJ3PO35Z

Clinical trials

8 trials

The current development programme across all trial phases — status mix, phase distribution and the late-stage studies shaping the evidence base.

Development programme
CLINICALTRIALS.GOV · LIVE REGISTRY
8
registered trials across all phases
LATEST COMPLETION 2021
3
Active studies
2
Recruiting
2
Late-stage (III+)
2
Completed
3
Discontinued
PHASE DISTRIBUTIONn = 8
Phase 14Phase 22Phase 2 / 32

Late-stage studies

Phase III+ trials still open or recently active — where late-stage evidence is being generated.

Recent completions

Trials that read out recently, adding to the completed evidence base.

Research activity

3 papers

Key research shaping understanding of this drug, combining the latest publications with the most influential evidence.

Publications over time
20212022
Major research themes3
Hydrogen3Methanol1Porphyrins1
Journals, researchers & institutions
Top journals
  • Chemical reviews2
  • Small (Weinheim an der Bergstrasse, Germany)1
Leading researchers
  • Capaldo L1
  • Daw P1
  • Fagnoni M1
  • Fornasiero P1
  • Gaikwad RP1
  • Gawande MB1
  • Kumar A1
  • Milstein D1
Leading institutions
free-text, unnormalised
  • Centre for Converging Technologies1
  • CICECO-Aveiro Institute of Materials1
  • Indian Institute of Science Education and Research Berhampur1
  • Institute of Chemical Technology1
  • Nanotechnology Centre1
  • Regional Centre of Advanced Technologies and Materials1

Related drugs

1 matches

Drugs sharing diseases, protein targets and literature with this one. Ranked by graph evidence (shared targets + diseases weighted above co-mentions).

Frequently co-studied with Hydrogen in the research literature.

1 shared paper
References & data sources
  • RxNorm (U.S. National Library of Medicine) — drug identity
  • ChEMBL (EMBL-EBI) & UniProt — pharmacology and targets
  • Europe PMC — research literature
  • ClinicalTrials.gov — clinical trials